Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity
about
Computational methods in drug discoveryA Cell Biologist's Field Guide to Aurora Kinase InhibitorsAurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells.Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping StrategyIdentification of Aurora-A Inhibitors by Ligand and Structure-Based Virtual Screening.Comprehensive structural and functional characterization of the human kinome by protein structure modeling and ligand virtual screening.The discovery of aurora kinase inhibitor by multi-docking-based virtual screening.The hunt for antimitotic agents: an overview of structure-based design strategies.Facile identification of dual FLT3-Aurora A inhibitors: a computer-guided drug design approach.A cell-based assay for screening spindle checkpoint inhibitorsIn-silico profiling of the biological activities of Amaryllidaceae alkaloids.Molecular docking of 1H-pyrazole derivatives to receptor tyrosine kinase and protein kinase for screening potential inhibitors.Combined 3D-QSAR modeling and molecular docking studies on pyrrole-indolin-2-ones as Aurora A kinase inhibitors.Classification of Aurora-A Kinase Inhibitors Using Self-Organizing Map (SOM) and Support Vector Machine (SVM).A dynamic mechanism for allosteric activation of Aurora kinase A by activation loop phosphorylation.Identification of ligand efficient, fragment-like hits from an HTS library: structure-based virtual screening and docking investigations of 2H- and 3H-pyrazolo tautomers for Aurora kinase A selectivity.3D-QSAR-assisted drug design: identification of a potent quinazoline-based Aurora kinase inhibitor.The multifaceted allosteric regulation of Aurora kinase A.
P2860
Q26997089-622570A5-D2AA-40FD-89DC-0B740AD0DA08Q27308125-1AB8B77D-F039-49D0-9586-AC51F3D0D8EEQ27680538-0FB4DFBF-4F03-4D19-91F6-344AF9175AF5Q27684168-6A77A82F-504E-4C72-9123-0353D7D5C6CDQ30009428-1DE9E371-3F6E-4029-A745-71DB988372EDQ30393891-96F5D5FC-CC94-4214-8BC9-30A7BE7D10BDQ34685403-361E397A-3AD0-4291-9E3B-6AF3342C2E07Q38808120-D97FCF3E-FB63-4A10-80B5-5811C70121E6Q39012096-09440D7B-E522-410C-92A7-6D2224CDD363Q39392895-43DBEF2F-0ABB-4C02-BEA7-8703ACE33D51Q40082701-33CCD9A6-0F7B-4FB9-A821-39289A1D5E0DQ41879831-CF92E5D4-551E-4712-9271-4648A28E3761Q41984158-ECC18F3B-3274-4969-82B9-6A4722939CB5Q47396117-B4BEC2B1-11A6-4B41-849B-A2C0551DAB21Q49713465-03BC2B9A-642B-408F-B72A-E9D77B463417Q54313399-E8C07758-B216-4489-AD77-6E865D2E9285Q54470261-B7446DA3-05E2-47CF-9DBC-0A078EBEA5BBQ55486788-BD525D3E-A134-419E-932F-22A5E0C5EB1C
P2860
Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Structure-based drug design of ...... is for potency and specificity
@ast
Structure-based drug design of ...... is for potency and specificity
@en
Structure-based drug design of ...... is for potency and specificity
@nl
type
label
Structure-based drug design of ...... is for potency and specificity
@ast
Structure-based drug design of ...... is for potency and specificity
@en
Structure-based drug design of ...... is for potency and specificity
@nl
prefLabel
Structure-based drug design of ...... is for potency and specificity
@ast
Structure-based drug design of ...... is for potency and specificity
@en
Structure-based drug design of ...... is for potency and specificity
@nl
P2093
P50
P356
P1476
Structure-based drug design of ...... is for potency and specificity
@en
P2093
Ajay Kumar Dixit
Chun-Hwa Chen
Chun-Yu Chang
Jian-Sung Wu
Jiun-Shyang Leou
John T-A Hsu
Paritosh Shukla
Su-Ying Wu
Tzu-Wen Lien
Uan-Kang Tan
P304
P356
10.1021/JM801270E
P407
P577
2009-02-26T00:00:00Z